Endocycle-related tubular cell hypertrophy and progenitor proliferation recover renal function after acute kidney injury

Elena Lazzeri1,2, Maria Lucia Angelotti1,2, Anna Peired1,2, Carolina Conte1,2, Julian A. Marschner3, Laura Maggi2, Benedetta Mazzinghi4, Duccio Lombardi1,2, Maria Elena Melica1, Sara Nardi1,2, Elisa Ronconi1,2, Alessandro Sisti1,4, Giulia Antonelli1,2, Francesca Becherucci4, Letizia De Chiara4, Ricardo Romero Guevara1,2, Alexa Burger5, Beat Schaefer6, Francesco Annunziato2, Hans-Joachim Anders3, Laura Lasagni1,2 & Paola Romagnani1,2,4

Acute kidney injury (AKI) is considered largely reversible based on the capacity of surviving tubular cells to dedifferentiate and replace lost cells via cell division. Here we show by tracking individual tubular cells in conditional Pax8/Confetti mice that kidney function is recovered after AKI despite substantial tubular cell loss. Cell cycle and ploidy analysis upon AKI in conditional Pax8/FUCCI2aR mice and human biopsies identify endocycle-mediated hypertrophy of tubular cells. By contrast, a small subset of Pax2+ tubular progenitors enriches via higher stress resistance and clonal expansion and regenerates necrotic tubule segments, a process that can be enhanced by suitable drugs. Thus, renal functional recovery upon AKI involves remnant tubular cell hypertrophy via endocycle and limited progenitor-driven regeneration that can be pharmacologically enhanced.
A cute kidney injury (AKI) is a global health concern impacting ∼13.3 million patients and 1.7 million deaths per year. AKI is defined by an acute deterioration of renal excretory function. If not lethal in the acute phase, AKI is considered reversible as implied by recovery of urine production and biomarkers of renal function. However, even mild AKI episodes imply a substantial risk for subsequent chronic kidney disease (CKD), but the pathophysiological basis for this phenomenon remains uncertain. Indeed, the current pathophysiological concept involves the assumption that every tubular epithelial cell (TEC) surviving the injury phase has the potential to dedifferentiate and proliferate to replace lost cells or even re-epithelialize denuded tubule segments. This concept has been evidenced by immunolabelling for cell cycle markers, such as Ki-67, proliferating cell nuclear antigen (PCNA) or 5-bromo-2′-deoxyuridine (BrdU) uptake. As a second concept, tubule...
regeneration may also involve a specific subset of TECs, referred to as tubular progenitors. We set three hypotheses: (1) the overall capacity of tubular regeneration after injury is largely overestimated; (2) cell cycle markers may not consistently represent cell division; (3) regeneration is limited to tubular progenitors and other TECs entering the cell cycle after AKI undergo endocycle-related hypertrophy.

Results

Function recovery upon AKI masks a substantial TEC loss. To evaluate TEC loss and regeneration after AKI, we applied a lineage tracing approach using conditional Pax8rtTA;TetO.Cre; R26.Confetti (Pax8/Confetti) mice, enabling a doxycycline-induced random labeling of all TECs by permanent recombination of a single-color-encoding gene (red, yellow, green, or blue fluorescent proteins, RFP, YFP, GFP, and CFP; Supplementary Fig. 1a)12. Transient unilateral ischemia reperfusion injury (IRI) was then induced as detailed in Supplementary Fig. 1b, c. Tubular necrosis at day 2 was partially restored at day 30 and associated with some focal interstitial fibrosis (Supplementary Fig. 1d). Blood urea nitrogen (BUN) was unchanged, even if at day 30 a significant loss-of-kidney weight had occurred (Supplementary Fig. 1e, f). Since BUN was too insensitive to detect the decline of kidney function, we directly measured glomerular filtration rate (GFR). GFR strongly declined at day 1 and partially recovered at day 14 remaining stable thereafter indicating CKD after AKI (Fig. 1a). Lineage tracing up to day 30 showed the presence of single-colored clones in outer stripe of the outer medulla (OSOM) (Fig. 1b, c). Therefore, all further analyses focused on this area. Quantitative analysis revealed a substantial and sustained loss of 30.5 ± 2.8% of total Confetti-labelled TECs (Fig. 1d). Similar results were obtained when TEC loss was evaluated after immunostaining for aquaporin-2 (AQP2) to exclude from the count collecting ducts (23.8 ± 5.9%; Fig. 1d), or for aquaporin-1 (AQP1), to limit the analysis to proximal TECs up to the thin descending limb of the Henle’s loop (32.5 ± 7.1%; Fig. 1d and Supplementary Fig. 1g–i). No transgene leakage was observed in healthy or ischemic mice (Supplementary Fig. 1j, k). Similar data were obtained in glycercol-induced AKI, a model of toxic tubule necrosis, either when we quantified total Confetti or AQP2–Confetti TECs (Fig. 1e–h). Thus, function recovery upon AKI masks a substantial and sustained TEC loss.

A small TEC subset proliferates after AKI. To test the current dogma of kidney regeneration via mitotic cell division of surviving TECs, we quantified their progeny. Administration of a lower doxycycline dose to label few TECs enabled precise clone counts at day 30 after IRI (Supplementary Fig. 11, m). Healthy mice (T0), mice that underwent a prolonged washout for 30 days (age-matched controls, T30) and sham-operated mice presented a similar clone size frequency (Fig. 1j; NS, Eq. 1 in Methods). Of note, the percentage of single cell clones decreased from 92.4 ± 0.9% at T0 to 78.9 ± 0.9% at day 30 after IRI. By contrast, clones consisting of 2 or more cells increased from 7.4 ± 0.9% at T0 (6.4 ± 0.7 of doublets and 1 ± 0.2% of triplets) to 21.1 ± 0.9% at T30 after IRI (11.9 ± 1.5% of doublets, 4.3 ± 0.2% of triplets and 4.9 ± 1.4% of quadratics) (Fig. 1j, Eq. 3 in Methods). Newly generated cells, had replaced only 54.1 ± 10.1% of lost AQP2–TECs (Fig. 1k, Eq. 3 in Methods). The clones observed at day 30 after IRI represented 21.1 ± 0.9% of those AQP2–survived, but were the progeny of only 8.6 ± 1.6% of AQP2–TECs present at T0 (Fig. 1j, Supplementary Fig. 2, Eq. 2 in Methods). Similar results were obtained in the nephrotoxic AKI model, where 35.4 ± 5.7% of lost cells were replaced in each kidney (Fig. 1k, Eq. 3 in Methods) and ultimately derived from 3.5 ± 0.1% of AQP2–TECs present at T0 (Fig. 11, Eq. 2 in Methods). Together, these results show that upon AKI only a small TEC subset, undergoes mitosis to replace no more than ~50% of injured cells.

Kidney tubules contain a distinct Pax2+ cell subset. Using conditional Pax2rtTA;TetO.Cre;R26.Confetti (Pax2/Confetti) mice (Supplementary Fig. 3a), we recently identified Pax2+ cells of the Bowman’s capsule as progenitors regenerating podocytes upon glomerular injury13. These mice exhibited no leakage and Pax2 promoter fidelity as showed in Supplementary Fig. 3b–e and already previously reported14,15. Pax2+ cells were also found in a scattered pattern within tubules (Fig. 2a–h) along specific segments of the nephron (Fig. 2d). In particular, they represented 1.6 ± 0.5% of megalin+ TECs in S1 and S2 segments (Fig. 2h), 9.8 ± 0.9% of AQP1+ TECs in S3 segment (Fig. 2a, e) and 12.3 ± 1.2% of Tamm–Horsfall Protein+ (THP+ ) distal TECs (Fig. 2b, f).

Induction of cell labeling followed by 30 days washout or continued doxycycline exposure for the same period of time revealed stable numbers of Pax2+ cells (Fig. 2i–l). In addition, induction of cell labeling at 12 weeks of age (Supplementary Fig. 3f) revealed a number of Pax2+ cells similar to that observed in mice induced at 5 weeks of age (68.8 ± 4.9 vs. 62 ± 1.2; NS). Thus, Pax2+ TECs are a distinct and stable cell population in mice.

**Fig. 1** Only a small TEC subset proliferates after AKI and partially replaces lost TECs. a GFR in ischemic mice (n = 13) normalized on the GFR at baseline and on sham-operated control group (n = 5). One-way ANOVA post hoc Tukey. b, c Juxtaposed images of a Pax8/Confetti mouse kidney at day 0 (T0, n = 5) and day 30 after IRI (T30, n = 4). Arrows indicate single-color clones. OSOM outer stripe of outer medulla; ISOM inner stripe of outer medulla. d Number of Pax8+, Pax8+AQP2−, and Pax8+AQP1+ cells in Pax8/Confetti mice at day 0 (T0, white column, n = 5) and at day 30 after IRI (IRI T30, gray column, n = 4). Mann–Whitney test, *p < 0.05, **p < 0.01 IRI T30 vs. T0. e, f EUN in healthy Pax8/Confetti mice (n = 5) and in Pax8/Confetti mice after nephrotoxic AKI (n = 6). One-way ANOVA post hoc Tukey *p < 0.05 glycerol-treated mice vs. healthy. g FGR in Pax8/Confetti mice after nephrotoxic AKI (n = 7) normalized on the GFR at baseline and on healthy mice (n = 5). One-way ANOVA post hoc Tukey. g, h Number of Pax8+ cells in Pax8/Confetti mice at day 0 (T0, white column, n = 5) and day 30 after nephrotoxic AKI (Gly T30, gray with sparse pattern column, n = 4). Mann–Whitney test *p < 0.05 Gly T30 vs. T0. h Number of Pax8+AQP2− cells in Pax8/Confetti mice at day 0 (T0, white column, n = 5) and day 30 after nephrotoxic AKI (Gly T30, gray with sparse pattern column, n = 4). Mann–Whitney test *p < 0.05 Gly T30 vs. T0. i Single-colored clones in AQP2− tubules in Pax8/Confetti mice at day 30 after IRI (n = 4). AQP2 staining is white. j Clone frequency analysis of Pax8+AQP2− cells in Pax8/Confetti mice at day 0 (T0, n = 5), in age-matched controls (T30, n = 4), in sham-operated mice (n = 4), at day 30 after IRI (IRI T30, n = 4) and at day 30 after nephrotoxic AKI (Gly T30, n = 4). Mann–Whitney test *p < 0.05 IRI T30 vs. T0, sham and Gly T30 vs. T0 and T30. k Percentage of Pax8+AQP2− cells in Pax8/Confetti mice at day 0 (T0, n = 5), at day 30 after IRI (IRI T30, n = 4) and at day 30 after nephrotoxic AKI (Gly T30, n = 4). Mann–Whitney test *p < 0.05 IRI T30 and Gly T30 vs. T0. l Percentage of Pax8+AQP2− clonogenic cells (gray column) in Pax8/Confetti mice at day 30 after IRI (IRI T30, n = 4) and at day 30 after nephrotoxic AKI (Gly T30, n = 4) vs. day 0 (n = 5). The white column is the percentage of Pax8+AQP2− that did not generate clones. Data are mean ± SEM. Scale bars 40 μm. Pax8+= Pax8 lineage-positive cells.
Fig. 2 Kidney tubules contain a distinct, predefined Pax2 lineage-positive tubular cell subset. a–c Juxtaposed confocal images of a kidney section from cortex to inner stripe of outer medulla in adult Pax2/Confetti mice (n = 4). Confetti reporter shows Pax2 lineage-positive single cells scattered within the proximal tubules, distal tubules and collecting ducts as demonstrated by immunolabelling for AQP1 (a), THP (b) and AQP2 (c), respectively (white). OSOM outer stripe of outer medulla; ISOM inner stripe of outer medulla. Scale bars 40 µm. d Schematic localization of Pax2− lineages-positive cells (red dots) in the proximal tubule, stained by AQP1 (light gray), in the thick ascending limb and in the distal tubule, stained by THP (dark gray), of the nephron. e–h Representative images of a kidney section in healthy Pax2/Confetti mice showing (n = 4) the distribution of Pax2 lineage-positive cells in S3 segment of proximal tubules (AQP1+, white) (e), in thick ascending limbs and distal tubules (THP+, white) (f), in collecting ducts (AQP2+, white) (g) and in S1–S2 segment of proximal tubules (Megalin+, white) (h). Scale bars 20 µm. i Experimental schemes. j, k Representative images of a kidney section in the OSOM of Pax2/Confetti mice showing Pax2+–AQP2− cells after 30 days of washout (T30, n = 5) (j) and after 30 days with doxycycline (doxycycline T30, n = 4) (k). AQP2 staining is white. l Number of Pax2+–AQP2− cells in OSOM of Pax2/Confetti mice at T30 (n = 5) and after 30 days with doxycycline (doxy T30, n = 4). Mann–Whitney test NS. Data are mean ± SEM. Scale bars 20 µm. Pax2+ = Pax2 lineage-positive cells.
(Supplementary Fig. 4a). BUN and GFR measurements gave similar results to those obtained in Pax8/Confetti mice (Supplementary Fig. 4b and Fig. 3a). This study revealed single-colored clones (Fig. 3b–d) up to 10 cells within S3 segments resulting in an increase number of Pax2+AQP2− TECs per field (Fig. 3e; p < 0.05) after IRI. Clone size frequency analysis at T0, T30, and in sham-operated mice showed similar percentages of clones (Fig. 3f; NS, Eq. 1 in Methods). Of note, the percentage of single cell clones at T0 decreased from 97.7 ± 0.2% to 76.4 ± 1.8% at day 30 after IRI (Fig. 3f, Eq. 1 in Methods). By contrast, clones consisting of 2 or more cells increased from 2.2 ± 0.2% (only doublets) to 23.6 ± 1.8% (15.2 ± 0.6% of doublets, 5.1 ± 0.8% of triplets and 3.3 ± 0.7% ≥4 cells, with single colored clones of up to 10 cells; Fig. 3f, Eq. 1 in Methods section). Accordingly, 30 days after IRI newly generated Pax2+AQP2− TECs, appeared and significantly increased the total number of Pax2+AQP2− TECs.
in comparison to T0 (Fig. 3g, Eq. 3 in Methods). Following IRI and expansion of Pax2+ cells, Pax2 immunolabelling was present also on many TECs not expressing the Confetti reporter, implying TECs could acquire Pax2 expression upon injury (Supplementary Fig. 4c). Consistently, many Pax2− immunolabelled cells in Pax8/Confetti mice were not found clonogenic (Supplementary Fig. 4d).

The enrichment of Pax2+ TECs labeled by the Confetti reporter (Fig. 3h) was related to both an increased survival capacity (Fig. 3i, Eq. 4 in Methods), as well as to a higher clonogenic capacity (Fig. 3d, Eq. 2 in Methods). Indeed, while Pax8+ cells were significantly reduced, Pax2+ cells were expanded in comparison to day 0 (Fig. 3k, Eq. 5 in Methods). Similar results were obtained in nephrotoxic AKI (Fig. 3l, o and Supplementary Fig. 4e, Eqs. 4, 2 and 5 in Methods).

No transgene leakage was observed in Pax2/Confetti ischemic mice (Supplementary Fig. 4f). These results demonstrate that during AKI Pax2+ TECs display increased survival and capacity to undergo mitosis in comparison to other TECs.

**Pax2+ cells regenerate long tubule segments.** We then checked the distribution of Pax2+ clones in the different tubule segments after immunolabelling for megalin, AQP1, THP, and AQP2 (Fig. 4a–d). The great majority of Pax2-derived clones formed in the S3 segment and less in the TAL of Henle’s loop (Fig. 4e, Eq. 7 in Methods), the two tubule segments of the outer medulla where tubule necrosis occurs. By contrast, only few clones formed in the S1–S2 segments in the cortex or in collecting ducts (Fig. 4e, Eq. 7 in Methods). The percentage of clonogenic cells was not significantly different between a 2D and 3D analysis performed in 40 µm thick sections (Fig. 4f, Eq. 2 in Methods). However, the 2D analysis slightly overestimated the percentage of clonogenic cells due to long clones being mistakenly counted as several smaller ones (Fig. 4f). Indeed, 2D assessment allowed identification of clones of up to 10 cells, while 3D analysis revealed single colored Pax2+ clones up to 98 cells regenerating long tubule segments (Fig. 4g–i and Supplementary Movie 1). These results demonstrate that pre-existing populations of Pax2+ cells regenerate necrotic tubule segments in the injured outer medulla.

**Drugs stimulating regeneration after AKI act selectively on Pax2+ TECs.** We then evaluated if proliferation is limited to Pax2+ cells or involves also other TECs. To this aim, we treated Pax2/Confetti mice with drugs that were previously reported to stimulate tubular regeneration after AKI, act cycling cells over the total of Pax2+ TECs (Fig. 5g–k). These results show that HDAC inhibitors, that stimulate tubular regeneration after AKI, act selectively on Pax2+ cells.

**Cell cycle markers do not predict cell division after AKI.** The finding that only Pax2+ TECs divide upon IRI was in conflict with immunolabelling of Ki-67 (expressed from late G1 to mitosis7, Fig. 6a–d), or PCNA, (expressed from late G1 to early G220, Fig. 6e–h). Indeed, we found diffuse tubular Ki-67 (Fig. 6b, d), as well as PCNA (Fig. 6f, h) positivity 2 days after injury suggesting many more TECs proliferate than actually proven by clone analysis in Pax8/Confetti mice. To clarify this apparent inconsistency we crossed Pax8−, as well as Pax2 rtTA;TetO.Cre; mice with harboring the fluorescent ubiquitin-based cell cycle indicator (FUCCI2) Cre-dependent reporter (Supplementary Fig. 6a, b), which consists of two fluorescent proteins whose expression alternates based on cell cycle phase: mCherry-hCdtd1 (red color), expressed in G1, and mVenus-hGemm (green color), expressed in S/G2/M21 (Supplementary Fig. 6c). Cells can also appear as yellow at the G1/S boundary.22 Experimental designs are detailed in Supplementary Fig. 6d, e.

Based on Pax8/FUCCI2 mice evaluated by confocal microscopy (Fig. 6i–k and Supplementary Fig. 6f–h) few TECs appeared in S/G2/M (mVenus+) at day 2 after IRI despite widespread tubular Ki-67 positivity (13.2 ± 3.4% vs. 47.1 ± 9.2%; p < 0.05 Mann–Whitney test; Fig. 6i, l vs. Fig. 6b, d). Interestingly, when Pax2/FUCCI2 mice were evaluated by confocal microscopy (Fig. 6m–o and Supplementary Fig. 6i–k), the percentage of cycling cells over the total of Pax2+ FUCCI2+ cells was higher (40.6 ± 1.7%; Fig. 6n, p), but the number per field was comparable to that of the Pax8/FUCCI2 mice (10.7 ± 0.4 in Pax8/FUCCI2 mice).
vs. 10.9 ± 0.3 in Pax8/FUCCI2 mice, NS) (Fig. 6n vs. Fig. 6j). These results suggested that numerous TECs entered the cell cycle but only few progressed toward the G2/M phase, i.e., mitosis. Both in Pax8/FUCCI2 and Pax2/FUCCI2 mice TECs were selectively labeled, as shown in Fig. 6i–k and Fig. 6m–o with Phalloidin staining and as previously reported23,24. No transgene leakage was observed in healthy or ischemic mice (Supplementary Fig. 6l–q). We thus performed immunolabelling for a marker commonly considered to label only cells in the G2/M phase, serine 10-phosphorylated histone H3 (p-H3)25–27. As expected, a lower percentage of TECs at day 2 was p-H3+ in comparison to Ki-67 (11.9 ± 1.1% vs. 47.1 ± 9.2%, p < 0.05, Supplementary Fig. 6r and Fig. 6d). P-H3+ TECs were mostly mVenus+, confirming that they were in G2/M (Fig. 6q, s). However, unexpectedly, also some Pax8+ TECs in G1 (mCherry+) were labeled (Fig. 6q). At day 30, mCherry+p-H3+ cells strongly increased, representing about a half of FUCCI2+p-H3+ TECs (Fig. 6r, s). By contrast, in Pax2/FUCCI2 mice, p-H3 mostly co-labeled mVenus-expressing

---

**Figure e**

Frequency of Pax2+ clones (%)% of clonogenic cells

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure f**

| 2D  | 3D  | 2D  | 3D  |
|-----|-----|-----|-----|
| 0   | 10  | 20  | 30  |
| 4   | 5   | 6   | 7   |

---

**Figure g**

Megalin AQP1

---

**Figure h**

AQP1 THP

---

**Figure i**

Collecting ducts

---

**Figure j**

Frequency of Pax2+ clones (%)% of clonogenic cells

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure k**

**Frequency of Pax2+ clones (%)% of clonogenic cells**

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure l**

**Frequency of Pax2+ clones (%)% of clonogenic cells**

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure m**

**Frequency of Pax2+ clones (%)% of clonogenic cells**

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure n**

**Frequency of Pax2+ clones (%)% of clonogenic cells**

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |

---

**Figure o**

**Frequency of Pax2+ clones (%)% of clonogenic cells**

| 0  | 10  | 20  | 30  | 40  | 50  | 60  | 70  | 80  | 90  | 100 |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0  | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** | **2** |
cells (Fig. 6t–v). This implies that Pax2+p-H3+ cells were truly in G2/M phase. These results document that Ki-67, PCNA, and p-H3 do not reliably indicate TEC proliferation after AKI.

**Pax8+ TECs endocyte while Pax2+ cells complete mitosis.**
The aforementioned data, together with the results obtained with the Confetti models, consistently suggested that most TECs might undergo alternative cell cycles without cell division. Indeed such alternative cycles, e.g., endoreplication cycles or endocycles, have recently been reported to drive polyploidy and hypertrophy upon tissue injury. To evaluate this possibility in AKI, we combined DNA content analysis with detection of FUCCI2 fluorescence by flow cytometry. Indeed, using this approach, G2/M diploid cells, which express mVenus and represent truly cycling cells can be distinguished from G1 polyploid cells which express mCherry and instead represent mononucleated endoreplicating cells (Fig. 6w–z). Pax8/FUCCI2 mice 2 days after IRI showed 9.8 ± 0.7% of Pax8+ TECs in S phase, but only 2 ± 0.5% in G2/M phase (Fig. 6w, y). Lineage tracing of mice for 30 days showed a consideralre increase of Pax8+ TECs that expressed mCherry but displayed a polyploid DNA content (≥4C) (2.1 ± 0.1% at day 2 vs. 13.5 ± 1.4% at day 30, <0.05, Mann–Whitney test; Fig. 6w, y). By contrast, cells with an abnormal DNA content were not observed in Pax2/FUCCI2 mice, either at 2 or 30 days (Fig. 6x, z). Rather, 2 days after IRI 35 ± 4.8% of Pax8+ cells were in the S phase, suggesting a higher proliferation capacity than Pax8+ cells (Fig. 6y, z). The gating strategy used to analyse FUCCI2+ cells and to avoid counting cell doublets as a potential source of artifacts is shown in Supplementary Fig. 7. Given our extremely conservative gating strategy, we certainly underestimated the percentage of endocycling cells. Similar results were obtained after deleting AQP2+ cells from the analysis (Supplementary Fig. 7b–e). These results show that Pax2+ cells frequently and efficiently divide, while other TECs endocyte into polyploid mononuclear TECs.

**Pax2+ cells proliferate while other TECs undergo hypotrophy.**
To validate these results, we used two further transgenic mouse lines, based on the FUCCI2aR reporter, a recent advancement of the FUCCI2 reporter which produces iso-stoichiometric quantities of both FUCCI probes expressed during all the cell cycle, with higher sensitivity and labeling of the cells during all the cell cycle phases.

The generation of Pax8::rtTA:TetO::Cre::FUCCI2aR, as well as Pax2::rtTA:TetO::Cre::FUCCI2aR transgenic mouse lines, experimental design and controls are detailed in Methods and in Supplementary Fig. 8. Both transgenic lines showed a percentage of induction higher than 90%.

The experimental procedure is summarized in Fig. 7a. Total renal cell suspensions were analysed by MacsQuant flow cytometry at time 0, day 2 and day 30 after IRI. As expected, the percentage of Pax8/FUCCI2aR-labeled tubular cells over total renal cells was about 10 times higher than that of Pax2/ FUCCI2aR cells (Fig. 7b–j and Supplementary Fig. 9). However, this was only related to a higher percentage of mCherry+ cells, as the percentage of mVenus+ cells was similar (Fig. 7k–j and Supplementary Fig. 9), suggesting that virtually only Pax2+ cells divide after AKI. The MacsQuant flow cytometer also automatically quantified the number of cells/μl of the different populations contained in the total renal cell suspensions. Counts confirmed the massive TEC loss in Pax8/FUCCI2aR mice 2 days after IRI, that was only partially recovered after 30 days as found before (Fig. 7k). Interestingly, the number of newly generated cells at day 30 in comparison to day 2 in Pax8/FUCCI2aR and Pax2/FUCCI2aR mice was similar (Fig. 7j). Pax2/FUCCI2aR cell numbers at day 30 were significantly expanded in comparison to day 2 (Fig. 7k), passing from 12.6 ± 1.4% of Pax8/FUCCI2aR total cells at day 0 to 19.5 ± 2.2% at day 2 and to 28.9 ± 3.4% at day 30 (Fig. 7m). Strikingly, absolute counts showed that the number of proliferating cells (mVenus+ and mCherry+mVenus+) in Pax8/ FUCCI2aR and in Pax2/FUCCI2aR mice was virtually identical at all time points analysed (Fig. 7n), demonstrating that only Pax2+ cells divide after AKI. Confocal microscopy showed expression of KIM-1 protein at day 30 by 71.7 ± 4.7% of Pax8+ mCherry+ TECs, vs. only 2 ± 1.2% of Pax2+ mCherry+ TECs, further underlining the different survival capacity of Pax2+ cells in comparison to other TECs (Supplementary Fig. 8i, m).

We then analysed the occurrence and distribution of endo- cycle. Consistent with results obtained in FUCCI2 mice, endocycling cells were only observed in Pax8/FUCCI2aR mice (Fig. 7o–q). In addition, 27.9 ± 4.6% of LTA+ proximal tubular cells in S1–S2 segments were p-H3+ mCherry+, representing endocycling cells, in comparison to 1.8 ± 0.8% of LTA+ proximal tubular cells that were mVenus+, the only truly dividing cells (Fig. 7r–t). Immunolabelling for AQP2 showed that the great majority of endocycling cells localized in the cortex (22.3 ± 3.4% in the cortex vs. 7.8 ± 2.2% in the OSOM), while the majority of truly proliferating cells localized in the OSOM (9.2 ± 1.6% in the OSOM vs. 3.1 ± 1.1% in the cortex, Fig. 7u). Endocycling cells in G1 (Pax8+ mCherry+p-H3+TECs) displayed an increased size in comparison to cycling cells in G1 (Pax8+ mCherry+p-H3+TECs) as confirmed by comparing their cell surface area by confocal microscopy (Fig. 7v, w).

Taken together, Pax2+ cells in the OSOM are the cells that regenerate injured tubules after AKI by mitotic cell division, while other TECs of the S1 and S2 segments rather enter endocycles to undergo hypotrophy. Both mechanisms may compensate for the irreversible loss-of-TECs occurring during AKI.

Endocycle is detected in kidneys of patients with CKD after AKI. To verify the presence of endocycling cells in human, we examined kidney biopsies from 10 cases of CKD after AKI and 5 healthy controls (Table 1). To detect endocycling cells in human, we applied the same strategy previously validated in the mouse, and searched for p-H3+ cells in G1 phase, the latter identified by

---

**Fig. 4** Pax2 lineage-positive cells regenerate long tubule segments. a Representative image of a kidney section showing single-colored clones in S1–S2 segments of proximal tubule as demonstrated by staining with anti-megalin antibody (white) in Pax2/Confetti mice at day 30 after IRI (n = 5). Scale bar 20 μm. b, c Representative images of a kidney section showing single-colored clones in S3 segment of proximal tubule as demonstrated by staining with anti-AQP1 antibody (white) in OSOM of Pax2/Confetti mice at day 30 after IRI (n = 5). Scale bars 20 μm. d Representative image of a kidney section showing single-colored clones in thick ascending limb as demonstrated by staining with anti-THP antibody (white) in Pax2/Confetti mice at day 30 after IRI (n = 5). Scale bar 20 μm. e Frequency of Pax2+ clones in S1–S2 segment of proximal tubules (Pax2+ Megalin+ clones, n = 5), in S3 segment of proximal tubules (Pax2+AQP1+ clones, n = 7), in thick ascending limbs (TAL, Pax2+THP+ clones, n = 7) and in the collecting ducts (Pax2+AQP2+ clones, n = 7) at day 30 after IRI. Mann–Whitney test. *p < 0.01 S3 vs. S1–S2 and collecting ducts, *p < 0.05 S3 vs. TAL and TAL vs. collecting ducts. f Percentage of clonogenic cells per field in 2D vs. 3D analysis in Pax2/Confetti and in Pax8/Confetti mice at day 30 after IRI vs. T0. (n = 5 Pax2/Confetti mice and n = 5 Pax8/Confetti mice). Mann–Whitney test NS. g–i 3D reconstruction of single-colored clones in Pax2/Confetti mice at day 30 after IRI (n = 5). DAPI counterstains nuclei (white). Scale bars 50 μm. Data are mean ± SEM. Pax2+ = Pax2 lineage-positive cells, Pax8+ = Pax8 lineage-positive cells.
CDK4 positivity, a kinase selectively expressed along the nuclear membrane in cells in G1 cell cycle phase\(^3\). Triple positivity of nuclear membrane CDK4, nuclear p-H3, and the proximal tubule marker Lotus Tetragonolobus Lectin (LTA) revealed that 44.9 ± 7.6% of proximal TECs in biopsies vs. 8.5 ± 3.5% in control kidneys were endocycling cells (Fig. 8a–e). By contrast, 7.9 ± 1.3% of proximal TECs in biopsies were single labeled for p-H3 vs. 3.8 ± 1.7% in control kidneys suggesting these were the only truly cycling cells. When endocycling cells were evaluated on all the tubular cells by colabelling for Phallolidin, the percentage declined to 18 ± 3.1% in biopsies vs. 2.9 ± 2.2% in control kidneys, suggesting endocycling cells are highly enriched in cortical proximal tubules (Fig. 8f). Consistently, fluorescence in situ hybridization for the Y chromosome on Phallolidin-stained biopsies detected 19.1 ± 4.3% of TECs with two, and 1.9 ± 0.7% of TECs with three or more Y chromosomes but a single nucleus (Fig. 8g, h). These cells were not observed in healthy controls.

These observations validate the experimental data from mice in patients with CKD after AKI and show that the majority of TECs stained by “proliferation markers” undergo endocycle-mediated hypertrophy.

**Discussion**

In this study, we questioned the current paradigm that functional recovery after AKI relates to a regenerative capacity of all TECs\(^5,6\). Indeed, our data demonstrate that: (1) AKI involves a permanent loss of TECs even when GFR recovery occurs; (2) Pax2+ TECs are endowed with higher resistance to death and clonogenic capacity and are responsible for both spontaneous and drug-enhanced regeneration of necrotic tubule segments after AKI; (3) Only Pax2+ TECs complete mitosis, while other TECs rather undergo endoreplication-mediated hypertrophy; (4) Endocycle is a dominant TEC response upon AKI also in humans.

Previous studies concluded on a diffuse proliferative response of surviving TECs based on immunolabelling for cell cycle proliferation markers, a technical approach obviously unable to verify cell division\(^5,7,25\). Indeed, TECs with mitotic figures are
rarely found in AKI kidneys31. Using three independent techniques, we found that only a small subset of TECs undergoes mitosis and contributes to kidney regeneration. To address the discrepancy between widespread positivity of proliferation markers and limited clonal cell division, we first evaluated the possibility that the tubule contains a progenitor population dedicated to replacement of lost TECs using lineage tracing of Pax2+ cells, a putative intratubular progenitor population. Pax2+ cells are mostly located in the S3 segment and the distal tubule, the tubule segments injured in ischemic or toxic AKI32, reminiscent of another subset of possible tubular progenitors characterized by Sox9 expression33,34. Our lineage tracing strategy unambiguously...
excluded upregulation of Pax2 expression upon AKI as a confounding factor. Rather, Pax2+ cells represented a distinct tubular cell subpopulation and were more resistant to death, explaining why some TECs survive an injury killing most of the other TECs. This was further highlighted by their lack of expression of the TEC injury marker KIM-1 that was instead largely upregulated by other TECs upon IRI. Moreover, Pax2+ cells displayed high clonogenic activity, and were the only TECs to efficiently complete mitosis after AKI, regenerating even long tubule segments. Indeed, 3D evaluation of regenerated tubule segments revealed very long Pax2+ clones that were not visible with the classical 2D analysis that underestimated the length of clones. Interestingly, being unable to detect long clones, the 2D analysis slightly overestimated the percentage of dividing TECs, even if the difference was not statistically significant when 40 μm thick 3D sections were compared with 2D images. This suggests that the percentage of dividing TECs would likely even be lower when analyzing the whole organ. Taken together these results indicate that new tubular cells arise exclusively from pre-existing labeled cells at T0 (mCherry+ cells). This new paradigm of widespread TEC proliferation contributing to kidney regeneration after AKI and rather imply that TEC endocycle-mediated hypertrophy enhances kidney function recovery after injury. Consistently, in Drosophila melanogaster, compensatory cellular hypertrophy involves endoreplication. Indeed, the increased DNA content allows a higher transcription capacity that can facilitate an increase in cell size, as observed in our AKI models.

Thus, the results of this study rather suggest that the majority of TECs entering the cell cycle after AKI endocycle-mediated hypertrophy following TEC loss, conceptually similar to hypertrophy of remaining podocytes upon podocyte loss. Kidney regeneration occurs only via a limited clonal response from TEC progenitors resulting in net TEC loss, implying irreversible nephron loss and subsequent CKD. The more cells are lost, the earlier CKD becomes clinically apparent. Since TEC hypertrophy sustains only function but not tissue regeneration, the presence of endocycling TECs can serve as an indirect indicator of irreversible TEC loss and potentially as a prognostic indicator of the risk for CKD progression, as suggested by their detection in biopsies of patients that developed CKD after an AKI episode.

Finally, the results of this study propose tubular progenitors as a target for treatment of AKI. Indeed, treatment of mice with drugs that were previously reported to improve tissue regeneration following AKI, showed that their effect resulted from Pax2+ progenitor proliferation that avoids development of tissue fibrosis and CKD.

In conclusion, the renal response to AKI involves two crucial mechanisms: (1) endocycle-mediated hypertrophy of surviving TECs that contributes to recover renal function despite significant loss of renal mass; (2) survival and mitosis of tubular progenitors that provide TEC regeneration. These data challenge the current paradigm of widespread TEC proliferation contributing to kidney regeneration and identify Pax2+ progenitors as the cellular source of a limited intrinsic regenerative capacity of kidney tubules. Instead, endocycle-mediated hypertrophy and persistent tubular cell loss are the predominant features after AKI. Therapeutic targeting of tubular progenitors could be a valuable strategy to improve long-term AKI outcomes.

**Methods**

Pax8/Confetti mice and Pax2/Confetti mice. The Pax8rtTA;TetO.Cre;R26.Confetti (Pax8/Confetti) mice or the Pax2rtTA;TetO.Cre;R26.Confetti (Pax2/Confetti) mice were developed on a full C57BL/6 background by crossing the Confetti (Pax8/Confetti) mice at day 0 (a), 2 (b) and 30 after IRI (c) (n = 3 per group). d Percentage of Ki-67+ cells over Phalloidin+ TECs at T0, IRI T2, and IRI T30 (n = 3 per group). e-g PCNA + cells at T0 (e), IRI T2 (f), and IRI T30 (g) (n = 5 per group). h Percentage of PCNA+ cells over TECs at T0, IRI T2, and IRI T30 (n = 5 per group). i-j mCherry+ (red) and mVenus+ (green) in Pax8/Fucci2 mice at T0 (i), IRI T2 (j), and IRI T30 (k) (n = 4 per group). Phalloidin staining is white. l Percentage of mCherry+ cells, mVenus+ cells and mCherry+mVenus+ cells in Pax8/Fucci2 mice at T0, IRI T2, and IRI T30 (n = 4 per group). m-o mCherry+ cells (red) and mVenus+ cells (green) in Pax2/Fucci2 mice at T0 (m), IRI T2 (n) and IRI T30 (o) (n = 4 per group). Phalloidin staining is white. p Percentage of mCherry+ cells, mVenus+ cells and mCherry+mVenus+ cells in Pax8/Fucci2 mice at T0, IRI T2, and IRI T30 (n = 4 per group). q-r m Cherry+ cells (red), mVenus+ cells (green) and p-H3+ cells (blue) in Pax8/Fucci2 mice at T0 (q) and IRI T30 (r) (n = 4 per group). Phalloidin staining is white. s Percentage of p-H3+ and mCherry+ cells and p-H3+mVenus+ cells in Pax8/Fucci2 mice at T0, IRI T2 and IRI T30 (n = 4 per group). t-u Details indicated by arrowheads and asterisks in q and s. v Percentage of p-H3+mCherry+ cells and p-H3+mVenus+ cells in Pax2/Fucci2 mice at IRI T2 and IRI T30 (n = 4 per group). w Cell cycle distribution of mCherry+, mVenus+, and mCherry+mVenus+ cells in Pax8/Fucci2 mice (w) and Pax2/Fucci2 mice (x) at IRI T2 (n = 4, left) and at IRI T30 (n = 5, right). Representative experiments are shown. y, z Percentage of cells over total Pax8/Fucci2 cells (y) and over total Pax2/Fucci2 cells (z) at IRI T2 (n = 4) and IRI T30 (n = 5). Data are mean ± SEM. Scale bars 20 μm. DAPI (white) counterstains nuclei. T0 = day 0, IRI T2 = day 2 after IRI, IRI T30 = day 30 after IRI.
Confetti strain Gr(ROSA)26Sor-m1(CAG-Brainbow2.1Cre)J with the TetO.Cre strain B6.Cg-Tg(TetO-Cre)1Jaw/J, both purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Double transgenic mice were then crossed with a Pax8.rtTA mouse (B6.Cg-Tg(Pax8-rTA2S*M2)fKo2c/J, Jackson Laboratory) or with a Pax2.rtTA mouse14, to obtain a triple transgenic inducible mouse model. Mice were genotyped and only triple hemizygous mice were used in this study.

Reporter transgene recombination was induced at 5 weeks of age by administration of 2 mg/ml or 0.25 mg/ml doxycycline hyclate (Sigma-Aldrich, St. Louis, MO, USA) for Pax8/Confetti and 2 mg/ml doxycycline hyclate for Pax2/Confetti mice in drinking water additioned with 2.5% sucrose (Sigma-Aldrich) for 10 days. Doxycycline administration induces a permanent recombination of a single color encoding gene (red, yellow, green, or blue fluorescent proteins, RFP, YFP, GFP, and CFP), with GFP cells occurring at lower frequency than other colors15. Further recombination outcome may also result in no fluorescent reporter labeling in Cre-expressing cells. Following the induction, mice were kept in a waterbath period of 1 week and were then killed (day 0, T0, n = 5 for Pax8/Confetti mice induced with 2 mg/ml doxycycline hyclate, n = 5 for Pax8/Confetti mice induced with 0.25 mg/ml doxycycline hyclate and n = 4 for Pax2/Confetti mice induced with 2.5% sucrose and n = 4 for Pax2/Confetti mice induced with 0.6% sucrose).
Pax2/Confetti mice) while another group was induced with doxycycline for 10 days and after the washout period underwent a unilateral IRI of 30 min (same procedure performed in Confetti mice), and were then killed at day 2 after IRI, IRI T30 = 4. Pax8/Fucci2aR mice and Pax2/Fucci2aR mice without induction were killed at day 30 after IRI (n = 6 for each transgenic mouse at each time point).

In the resulting mice, following doxycycline administration, Pax2 or Pax8 promoter drives the expression of the fluorescent protein mCherry–hCdt1 (30/120) (red) in nuclei of cells in G1 phase, and of the fluorescent protein mVenus–hGem (1/110) (green) in nuclei of cells in S/G2/M phase. Cells can also appear as yellow at the G1/S boundary, but this is a very short event and thus yellow cells are rare.

To verify if the transgenic system exhibited any type of leakage or non-specific transgene expression, Pax8/Confetti and Pax2/Confetti mice without induction were killed at T0 and at day 30 after IRI (n = 3 for each transgenic mouse at each time point). A percentage of endocycling mCherry+ cells and of mCherry+ cells (red) and p-H3+ cells (green) were evaluated by confocal microscopy or by flow cytometry. To perform confocal analysis, kidneys were processed as described for Confetti mice.

**Genotyping**

Tail biopsies were incubated overnight at 55 °C in lysis reagent (1 M Tris-HCl, pH 8.5; 0.5 M EDTA, 20% SDS, 4 M NaCl, 0.1 mg/ml proteinase K (K) in 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS (Sigma-Aldrich) for 2 h at 4 °C followed by immersion in a 15% sucrose solution in PBS for 2 h at 4 °C and, subsequently, in a 30% sucrose solution in PBS overnight at 4 °C, then frozen.

**Fig. 7** Pax2 lineage-positive cells proliferate, while other TEC endocyte and are persistently lost after AKI. A schematic procedure. b–f FACS analysis shows mCherry+ and mVenus+ cells in total renal cells of Pax8/Fucci2aR. (b, d) and Pax2/Fucci2aR mice (c, d) at T0, of Pax8/Fucci2aR (e, g) and Pax2/ Fucci2aR mice (f, g) at IRI T2 and of Pax8/Fucci2aR (h, j) and Pax2/Fucci2aR mice (i, j) at IRI T30. A representative experiment out of 4 is shown. k Number of total Fucci2aR cells in Pax8/Fucci2aR and Pax2/Fucci2aR mice at T0, IRI T2, IRI T30 (n = 4 in each group). Mann–Whitney test *p < 0.05. l Number of total Fucci2aR cells in Pax8/Fucci2aR and Pax2/Fucci2aR mice at IRI T30 in comparison to IRI T2 (n = 4 in each group). Mann–Whitney test N.S. m Percentage of Pax2/Fucci2aR over Pax8/Fucci2aR total cells at T0, IRI T2, IRI T30 (n = 4 in each group). Mann–Whitney test *p < 0.05. n Number of total mVenus+ cells mCherry+ mVenus+ cells in Pax8/Fucci2aR and Pax2/Fucci2aR mice at T0, IRI T2, IRI T30 (n = 4 in each group). Mann–Whitney test N.S. o p Cell cycle distribution of mCherry+, mCherry+mVenus+ cells in Pax8/Fucci2aR (o) and Pax2/Fucci2aR mice (p) at IRI T30. A representative experiment out of 4 is shown. q Percentage of endocycling cells in Pax2/Fucci2aR (black column) and Pax8/ Fucci2aR mice (light gray column) at IRI T30 (n = 4 in each group). Mann–Whitney test *p < 0.05. m Cherry+ cells (red) and p-H3+ cells (blue) in LATa + tubules in the cortex (white) of Pax8/Fucci2aR mice at IRI T30 (n = 5). Arrows show mCherry+ p-H3+ cells. r Detail of r, s mCherry+ cells (red) and mVenus+ cells (green) in LATa + tubules in the cortex (white) of Pax8/Fucci2aR mice at IRI T30 (n = 5). Arrows show mVenus+ cell. be percentage of endocycling cells (mCherry+ p-H3+) cells and cycling cells (mVenus+ cells) in the cortex of Pax8/Fucci2aR mice at IRI T30 (n = 5). Mann–Whitney test *p < 0.05. m Measurement of the cell surface area of mCherry+ p-H3+ cells and of mCherry+p-H3 cells after staining with Phalloidin (white) with Image J software in Pax8/Fucci2aR mice at IRI T30 (n = 4). w Cell surface area of mCherry+p-H3+ cells and of mCherry+p-H3+ cells (green) in LATa + tubules in the cortex (white) of Pax8/Fucci2aR mice at IRI T30 (n = 5). Mann–Whitney test ***p < 0.001. Data are mean ± SEM. Scale bars 20 µm. T0 = day 0, IRI T2 = day 2 after IRI, IRI T30 = day 30 after IRI.
Fig. 8 High percentage of endocycling TECs in the kidney of patients that developed CKD after AKI. 

a A healthy kidney section showing the expression of CDK4 (green) and p-H3 (red) in LTA+ proximal tubular cells (blue) \( (n = 4) \). b–d A renal biopsy section from a patient that developed CKD after AKI \( (n = 7) \) showing CDK4+p-H3+ (green and red cells, arrows) and CDK4–p-H3+ (red cells, arrowheads) or CDK4+p-H3– (green cells, arrowheads) in proximal tubular LTA+ cells (blue). d' Split images of the tubule shown in d. e Percentage of CDK4+p-H3+LTA+ cells over total proximal TECs (LTA+) in healthy kidneys \( (n = 4) \) and in renal biopsies from patients that developed CKD after AKI \( (n = 7) \). Mann-Whitney test \( *p < 0.05 \). f Percentage of CDK4+p-H3+ cells over total TECs in healthy kidneys \( (n = 4) \) and in renal biopsies from patients that developed CKD after AKI \( (n = 7) \). Mann-Whitney test \( *p < 0.05 \). g, g' A renal biopsy section from a patient that developed CKD after AKI \( (n = 8) \) showing the presence of two or three Y chromosome-probe (green) in TECs labeled with Phalloidin (red), at different magnifications. Arrowheads indicate doubled dots for Y chromosome in a nucleus. h High magnification of another biopsy field. Arrowhead indicates triple dots for Y chromosome in a nucleus. DAPI counterstains nuclei. Data are mean ± SEM. Scale bars 20 µm.
Table 1 List of patients with CKD after AKI analyzed in this study

| Patient | Gender | Age (years) | Diagnosis | Number and severity of AKI episode(s) | CKD stage | Time since last AKI episode(s) and biopsy (days) |
|---------|--------|-------------|-----------|--------------------------------------|-----------|-----------------------------------------------|
| 1       | M      | 10          | TIN       | 1× AKIN3                             | CKD2      | 45                                            |
| 2       | M      | 5           | IRI       | 2× AKIN3                             | CKD3      | 180                                           |
| 3       | M      | 59          | IRI       | 3× AKIN1                             | CKD4      | 365                                           |
| 4       | M      | 56          | Sepsis    | 1× AKIN3                             | CKD4      | 30                                            |
| 5       | M      | 73          | Light chain ATN | 1× AKIN1, 1× AKIN2               | CKD4      | 365                                           |
| 6       | M      | 57          | IRI       | 1× AKIN3                             | CKD3      | 1460                                          |
| 7       | F      | 30          | IRI       | 1× AKIN3                             | CKD3      | 45                                            |
| 8       | F      | 51          | IRI       | 1× AKIN3                             | CKD3      | 30                                            |
| 9       | M      | 44          | RCC-normal tissue | None | None |
| 10      | M      | 86          | RCC-normal tissue | None | None |
| 11      | M      | 26          | RCC-normal tissue | None | None |
| 12      | M      | 74          | RCC-normal tissue | None | None |
| 13      | F      | 51          | RCC-normal tissue | None | None |

TIN tubulointerstitial nephritis, IRI ischemia reperfusion injury, ATN acute tubular necrosis, AKIN Acute Kidney Injury Network criteria, number indicates stage, CKD chronic kidney disease, number indicates stage, RCC renal cell carcinoma

Renal ischemia reperfusion injury. Male mice were anesthetized by intraperitoneal injection of Ketamine (100 mg/kg)/Xylazine (10 mg/kg, Bio98 S.r.l., Milan, Italy), which produced short-term surgical anesthesia with good analgesia. The animals were kept warm in a 37 °C ventilated heating chamber before surgery and their body temperature was monitored constantly by a rectal probe and maintained in the range of 36.5–37 °C. The mouse was placed on a thermostatic station laying on the right side, shaved and disinfected with Povidone-iodine and an incision of 1–1.5 cm on the skin on the left side was performed, then the muscle layer below was cut and opened. The left kidney was then externalized pushing it out from the abdomen cavity. The duration of ischemia was 30 min, after which the clamp was removed to start the reperfusion, which is indicated by the change of the color changes, (visible by color change of the kidney from red to dark purple). The duration of kidney ischemia starts from the time of clamping. After verification of the color changes, the kidney was returned to the abdomen cavity and the animal returned to the ventilated heating chamber. For each time point, GFR value was normalized on the value at baseline and on the sham (for ischemic mice) or healthy mice of comparable age and weight (for glycerol-treated mice) value. Based on the results obtained in preliminary experiments to assess GFR measurement variability, only mice showing a drop of GFR after AKI of at least 20% over baseline were included in the study.

Estimation of blood urea nitrogen. Renal function was assessed by collecting a small amount of blood from mice (n = 5 Pax8/Confitetti ischemic mice, n = 5 Pax8/Confitetti sham-operated mice, n = 6 Pax8/Confitetti glycerol-treated mice, n = 5 Pax8/Confitetti healthy mice, n = 8 Pax2/Confitetti glycerol-treated mice, n = 5 Pax8/Confitetti healthy mice) with a metal lancet from submandibular plexus at different time points in order to measure BUN levels. Blood parameters were measured in EDTA anticoagulated plasma samples using Urea FS kit (DiaSys Diagnostic Systems, Holzheim, Germany), according to the manufacturer’s protocols.

Assessment of renal injury. Healthy and ischemic kidneys stored in 4% buffered formalin were embedded in paraffin and 2–4 μm sections were prepared for periodic acid–Schiff (PAS) staining. Ischemic tubular injury and scarring were evaluated by assessing the percentage of tubules in the outer stripe of outer medulla that displayed cell necrosis, tubular dilatation or cast formation (injury), atubular sections with abundant unorganized parenchyma cells and cell infiltrates (scarring). Twenty-four kidneys from Pax2/Confitetti mice and 4 fields (20×) per kidney were analyzed. All assessments were performed by a blinded observer.

Immunofluorescence and confocal microscopy. Confocal microscopy was performed on 10 μm sections of renal tissues by using a Leica SP5 AOBS confocal microscope (Leica, Wetzlar, Germany) equipped with a Chameleon Ultra-II two-photon laser (Coherent, Milan, Italy). After intramuscular injection on day 0 with hypertonic glycerol (8 ml/kg body weight of a 50% glycerol solution Sigma-Aldrich) into the inferior hind limbs.

Transcutaneous measurement of glomerular filtration rate. Measurement of the glomerular filtration rate (GFR) was done as described elsewhere. In brief, mice (n = 9 Pax2/Confitetti ischemic mice, n = 13 Pax8/Confitetti ischemic mice, n = 5 Pax8/Confitetti sham-operated mice, n = 5 Pax2/Confitetti sham-operated mice, n = 5 Pax8/Confitetti healthy mice, n = 5 Pax2/Confitetti healthy mice, n = 7 Pax8/Confitetti glycerol-treated mice, n = 8 Pax2/Confitetti glycerol-treated mice, n = 7 Pax8/Confitetti ischemic mice treated with DMSO, n = 6 treated with PBS, n = 7 treated with TSA, n = 6 treated with PBA) where anesthetized with isoflurane and a miniaturized imager device built from two light-emitting diodes, a photodiode and a battery (Mannheim Pharma and Diagnostics GmbH, Mannheim, Germany) were mounted via a double-sided adhesive tape to the shaved animals’ neck. For the duration of recording (~1.5 h) each animal was conscious and kept in a single cage. Prior to the intravenous injection of 150 mg/kg FITC-sinistrin (Mannheim Pharma and Diagnostics GmbH), the skin’s background signal was recorded for 5 min. After removing the imager device, the data were analyzed using MPD Studio software ver.RC6 (MediBeacon GmbH CubeX41, Mannheim, Germany). The GFR [μl/min] was calculated from the decrease of fluorescence intensity over time (i.e., plasma half-life of FITC-sinistrin) using a two-compartment model, the animals body weight and an empirical conversion factor. For each time point, GFR value was normalized on the value at baseline and on the sham (for ischemic mice) or healthy mice of comparable age and weight (for glycerol-treated mice) value. Based on the results obtained in preliminary experiments to assess GFR measurement variability, only mice showing a drop of GFR after AKI of at least 20% over baseline were included in the study.

The following antibodies were used: anti-aquaporin-1 (AQP1, AR2219, dilution 1:100, Millipore, Darmstadt, Germany), anti-Tamm-Horsfall (THP, CL1032A, dilution 1:20, Cedarlane, Burlington, Ontario, Canada), anti-aquaporin-2 (AQP2, C-17, SC-9882, dilution 1:25, Santa Cruz Biotechnology, Saint Louis, USA), anti-megalin (P-20, sc-16478, diluition 1:25, Santa Cruz Biotechnology), biotinylated Lotus Lectin, LTA (B-1325, dilution 1:50, Vector Laboratories, Burlingame, USA), anti-KIM-1 (AF1817, dilution 1:40, R&D Systems, Inc., Minneapolis, USA), anti-6000 (dilution 1:25, Zymed, Thermo Fisher Scientific, MA USA), anti-Ki-67 (ab15580, dilution 1:50, Abcam, Cambridge, UK), anti-EGP-488 (A21311, dilution 1:100, Life Technologies, Monza, Italy), anti-phosphorylated Histone 3 (p-H3, ab15955, dilution 1:300, Abcam), anti-cyclin dependent kinase 4 (CDK4, SC-601, dilution 1:50, Santa Cruz Biotechnology) and Phalloidin-633 (A22284, dilution 1:40, Life Technologies). Alexa-Fluor secondary antibodies were obtained.

Pax2.rTA and Pax8.rTA forward 5′-AACGACCTGTAAGCTTGTG-3′ and reverse 5′-GAATGGTTGATGTTGTTCTC-3′; TetO.Cre forward 5′-TCGCTGATTCAATCCGTACGTC-3′ and reverse 5′-CCATGAGAAACGACCTCGGTG-3′. TCRa genomic DNA was used as gene housekeeping for relative quantification and was amplified by using the forward 5′-CAAAATGTGTTGTTGTGC-3′ and the reverse 5′-GTCAGTCGAGTGCACGTATTT-3′ primers.

To distinguish Fucci2AR and Confitetti homozygosity from heterozygosity, PCR were performed with the following primers and parameters: Confetti forward 5′-GAATTAATTCGCCCATTAATCTC-3′ and reverse 5′-AAATGGCTTCGTAGTTGTTAT′, 3 min 94 °C, 35 cycles of 30 s 94 °C, 30 s 58 °C, 30 s 72 °C and, finally 2 min 72 °C; Fucci-P3 5′-TCCCTGCTGATCTGAACCTCGACGT-3′, Fucci-P4 5′-AAGCCCAATGACATCCATCTCCTC-3′ and Fucci-P4 5′-GGGAGGATGTTGGGAAACATAGC3′-2 min 96 °C, 35 cycles of 96 °C 30 s, 65 °C 30 s and, finally, 72 °C for 30 s.
from Molecular Probes (Life Technologies). For the detection of tubules, staining with Alexa Fluor 546 Phallolidin (A22283, dilution 1:40, Molecular Probes, Life Technologies) was performed. For the Pax8/Confetti mice and for Pax2/Confetti mice the acquisition was set in the cyan, green, yellow, and red wavelengths using 405, 488, 514, and 543 nm wavelength excitation, respectively. For Pax8/Fucci2i2 mice, Pax2/Fucci2i2, Pax8/Fucci2iAR, and Pax2/Fucci2iAR mice the acquisition was set in green and red wavelengths using 488, and 543 nm excitation, respectively. mCherry emission was collected through 570/620 nm BP. Nuclei were counterstained with DAPI (62248, dilution 1:1000, Life Technologies) excited with Chameleon Ultra-II two-photon laser at 800 nm.

Cell surface area of at least 20 mCherry−pH3− cells and 20 mCherry−pH3+ cells for each Pax8/Fucci2iAR mouse were measured using Image J software. One field is: 620 × 620 µm.

3D reconstruction. To generate 3D images (Fig. 4g–i) and Supplementary Movie 1, an image processing software from Leica Microsystems “Leica Aplicon Suite X” was used. Z-series stacks were obtained from 40 µm kidney slices, being this thickness the limit to stain all the nuclei with DAPI, permitting cell counting. Images were collected at 1 µm intervals. Clones were observed in every color, but for 3D reconstruction, we chose mostly the yellow ones cause the YFP is distributed in all the cell, making the 3D reconstruction easier to build and appreciate.

To compare 2D with 3D analysis, two blinded observers counted the number of clones in 2D images and in 3D reconstruction. The percentage of clonogenic cells was calculated as reported below (Eq. 2).

Immunohistochemistry. Immunohistochemistry for PCNA was performed in paraffin embedded healthy and ischemic kidney sections (n = 5 at day 0, n = 5 at day 2 and at day 30 after IRI), as detailed elsewhere44. Briefly, after removing the paraffin and rehydrating in water, the tissue sections were submerged in 3% H2O2 for 10 min to block the endogenous peroxidase activity. The target antigen was retrieved by microwaving the sections in sodium citrate buffer (10 mM, pH 6). The samples were heated in a microwave at 800 W for 3 min and then for 7 min at 400 W. The sections were cooled for 30 min at room temperature. After that, the 10-min heating procedure was repeated with fresh buffer. Sections were pre-incubated for 30 min in 1× PBS, 1% bovine serum albumin, 0.05% saponin and subsequently incubated for 15 min at 37 °C and overnight at 4 °C with mouse anti-PCNA (PC10, ab29, dilution 1:300, Abcam). Then, sections were incubated for 15 min at 37 °C and overnight at 4 °C with secondary biotynilated-anti mouse IgG antibody, followed by an incubation with avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector Laboratories) for 30 min, and 3-aminio-9-ethylcarbazole (AEC, Vector Laboratories) (red color) as peroxidase substrate for 20 min. Sections were counterstained with Eosin G (Bioprica, Milan, Italy).

Clone frequency analysis. Single-cell clones and clones with two or more cells were counted in AQP2− tubules of the outer stripe of outer medulla in Pax8/Confetti mice at day 0 (T0), in age-matched controls (T30), in sham operated, in ischemic kidneys (IRI T30) and in nephrotoxic kidneys (Gly T30).

For each clone size, clone frequency analysis showed in Fig. 1j, was assessed as follows:

\[
\text{Clone frequency} (\%) = \frac{n° \text{ of clones of } n \text{ cells}}{n° \text{ of } n \text{ clone}} \times 100. \tag{1}
\]

where 1 ≤ n ≤ 11 in Pax8/Confetti mice because this is the maximum clone size observed.

Same calculations were performed in Pax2/Confetti mice at T0, T30, sham operated and IRI T30 where 2 ≤ n ≤ 10 (Fig. 3b).

Clones observed in a total of at least 30 fields of outer stripe of the outer medulla taken from at least five sections of each mouse were counted by two independent blinded observers. Clone size was established by counting the nuclei counterstained with DAPI.

See Supplementary Methods for a representative calculation.

Clonogenic cell analysis. To establish the percentage of clonogenic cells in Pax8/Confetti mice we performed the following calculations:

(A) n° of new clones at day 30 after IRI (IRI T30):

\[
\sum_{n=2}^{11} \text{clones composed of } n \text{ cells at IRI T30} - \text{clones composed of } n \text{ cells at T0}, \tag{2}
\]

where 2 ≤ n ≤ 11 in Pax8/Confetti mice because the maximum clone size observed is 11 cells.

(B) % of clonogenic cells at IRI T30 in comparison to T0 (vs. T0) showed in Fig. 1L

\[
\left| \frac{A}{n°} \text{ of Pax8}^+ \text{cells at T0} \right| \times 100. \tag{4}
\]

Same calculations were performed in Pax2/Confetti mice where 2 ≤ n ≤ 10 (Fig. 3).

Same calculations were performed in Pax8 and Pax2 Confetti mice 30 days after nephrotoxic AKI (Gly T30, Fig. 1L, Fig. 3).

All the analysis was performed in tubular cells excluding collecting ducts (AQP2 immunostained) of the outer stripe of outer medulla. All counts were executed by two independent blinded observers.

See Supplementary Methods for a representative calculation.

Percentage of new cells after ischemic or nephrotoxic AKI. To establish the percentage of new cells in Pax8/Confetti mice at IRI T30 we performed the following calculations (Fig. 1K):

(C) n° of Pax8+ cells included in clones at IRI T30

\[
\sum_{n=2}^{11} \text{clones composed of } n \text{ cells at IRI T30} - \text{clones composed of } n \text{ cells at T0} \times n, \tag{3}
\]

where 2 ≤ n ≤ 11 in Pax8/Confetti mice because the maximum clone size observed is 11 cells.

(D) n° of new Pax8+ cells at IRI T30 = n° of Pax8+ cells included in new clones−n° of cells that originated new clones

\[
C = A \tag{5}
\]

* the n° of cells that originated new clones coincides with the n° of new clones at IRI T30 (A), because each clone is the progeny of one cell.

(E) % of new Pax8+ cells at IRI T30 in comparison to T0

\[
\left( \frac{D}{n°} \text{ of Pax8}^+ \text{cells at T0} \right) \times 100. \tag{6}
\]

Same calculations were performed in Pax8/Confetti mice after nephrotoxic AKI (Fig. 1K) and in Pax2/Confetti mice at day 30 after IRI (Fig. 3g). In Pax2/Confetti mice 2 ≤ n ≤ 10.

All the analysis was performed in tubular cells excluding collecting ducts (AQP2 immunostained) of the outer stripe of outer medulla. All counts were executed by two independent blinded observers.

See Supplementary Methods for a representative calculation.

Percentage of lost cells after ischemic or nephrotoxic AKI. To establish the percentage of lost cells in Pax2/Confetti mice after ischemic AKI, we performed the following calculations (Fig. 3i):

\[
100 - \left[ \frac{n° \text{ of Pax}^+ \text{cells at IRI T30} - D/n° \text{ of Pax}^+ \text{cells at T0}}{\text{of Pax}^+ \text{cells at T0}} \right] \times 100. \tag{4}
\]

Same calculations were performed in Pax8/Confetti mice after ischemic AKI (Fig. 3i) and in Pax2/Confetti and Pax8/Confetti mice after nephrotoxic AKI (Fig. 3m).

All the analysis was performed in tubular cells excluding collecting ducts (AQP2 immunostained) of the outer stripe of outer medulla. All counts were executed by two independent blinded observers.

See Supplementary Methods for a representative calculation.

Percentage of variation over T0. To establish the percentage of variation over T0 in Pax2/Confetti mice after ischemic AKI, we performed the following calculations (Fig. 3k):

\[
\frac{\left| \left( n° \text{ of Pax}^+ \text{cells at IRI T30/n° of Pax}^+ \text{cells at T0} \right) \times 100 \right|}{100}. \tag{5}
\]

Same calculations were performed in Pax8/Confetti mice after ischemic AKI (Fig. 3k) and in Pax2/Confetti and Pax8/Confetti mice after nephrotoxic AKI (Fig. 3o).

All the analyses were performed in tubular cells excluding collecting ducts (AQP2 immunostained) of the outer stripe of outer medulla. All counts were executed by two independent blinded observers.

Percentage of variation of Pax2+ cells and Pax2− cells over IRI. To establish the percentage of variation of Pax2+ cells over IRI in Pax2/Confetti mice after ischemic AKI and treatment with TSA or 4-PBA, we performed the following calculations (Fig. 5e):

\[
\left( n° \text{ of Pax}^+ \text{cells after treatment at IRI T30/n° of Pax}^+ \text{cells at IRI T30} \right) \times 100. \tag{6}
\]

Same calculations were performed for Pax2− cells (Fig. 5e). All counts were executed by two independent blinded observers.
Frequency of Pax2+ clones. This analysis was performed in the cortex after megalin immunostaining, in the OSOM after AQP1 and THP immunostaining and in the collecting ducts after AQP2 immunostaining.

To establish the frequency of Pax2+ clones in nephron segments and in collecting ducts, we performed the following calculations (Fig. 4e):

\[
(\text{F}) n^2 \text{ of total Pax2+ new clones at day 30 after IRI (IRI T30)} = \left( n' \text{ of new megalin}^+ \text{ clones} + n' \text{ of new AQP1}^+ \text{ clones} + n' \text{ of new THP}^+ \text{ clones} + n' \text{ of new AQP2}^+ \text{ clones} \right) / (A/F) \times 100.
\]

The \( n' \) of new clones was determined based on the calculation used in formula A.

G (G) frequency of Pax2+ clones (%) in each nephron segment and in collecting ducts was calculated using the formula:

\[
\text{G} = \left( \frac{n'}{(A/F)} \times 100 \right)
\]

Cell cycle analysis by flow cytometry. Cell cycle analysis was performed on total Fucci2 cells and on total Fucci2A/R cells (mCherry+ and mVenus+) cells in Pax8/Fucci2 mice, in Pax2/Fucci2 mice, in Pax8/Fucci2A/R mice, and in Pax2/Fucci2A/R mice at 2 days and at 30 days after IRI.

Pax8/Fucci2, Pax8/Fucci2A/R, Pax2/Fucci2, and Pax2/Fucci2A/R kidneys were processed as above and cells were incubated with anti-AQP2 pAb (bs-4611R, dilution 1:20, Bioss Inc.) followed by an Alexa Fluor 647 goat anti-rabbit as secondary antibody to detect mCherry

Fluorescence in situ hybridization analysis. Fluorescence in situ hybridization analysis was performed using Whole Chromosome Painting Probe for Y chromosome (WCPY) (Cytocept Ltd, Tarrytown, NY, USA) following the manufacturer’s instructions in combination with Phalloidin-546 (A22823, dilution 1:40, Life Technologies).

Study approval. Animal experiments were approved by the Institutional Review Board and by the Italian Ministry of Health and by the Ethical Committee of the “Regierung von Oberbayern” and performed in accordance with institutional, regional, and state guidelines and in adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were housed in a specific pathogen-free facility with free access to chow and water and a 12-h day/night cycle.

Statistical analysis. The results were expressed as mean ± SEM. Comparison between groups was performed by the Mann–Whitney U-test, or through the analysis of variance for multiple comparisons (ANOVA for repeated measures) with Tukey post hoc analysis. \( p < 0.05 \) was considered to be statistically significant.

Data availability. The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information Files or from the corresponding author upon reasonable request.

Received: 13 September 2016 Accepted: 8 March 2018

Published online: 09 April 2018

References

1. Mehta, R. L. et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 365, 1–28 (2015).

2. Bellomo, R., Kellum, J. A. & Ronco, C. Acute kidney injury. Lancet 380, 756–766 (2012).

3. Lameire, N. H. et al. Acute kidney injury: an increasing global concern. Lancet 382, 170–179 (2013).

4. Chawla, L. S., Eggers, P. W., Star, R. A. & Kimmel, P. L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Engl. J. Med. 371, 58–66 (2014).

5. Sharifuddin, A. A. & Molitoris, B. A. Pathophysiology of ischemic acute kidney injury. Nat. Rev. Nephrol. 7, 189–200 (2011).

6. Zak, A. & Bonventre, J. V. Acute kidney injury. Annu. Rev. Med. 67, 293–307 (2016).

7. Lombardi, D., Becherucci, F. & Romagnani, P. How much can the tubule regenerate and who does it? An open question. Nephrol. Dial. Transplant. 13, 462–469 (2015).

8. Angelotti, M. L. et al. Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury. Stem Cells 30, 1714–1725 (2012).

9. Rinkevich, Y. et al. In vivo clonal analysis reveals lineage-restricted progenitor characteristics in mammalian kidney development, maintenance, and regeneration. Cell Rep. 7, 1270–1283 (2014).

10. Kang, H. M. et al. Sox9-positive progenitor cells play a key role in renal tubule epithelial regeneration in mice. Cell Rep. 14, 861–871 (2016).

11. Traylor-Krausch, M. et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat. Med. 14, 979–984 (2008).

12. Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral regeneration. Nat. Cell Biol. 10, 263 (2008).

13. Lasagni, L. et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Cell Stem Cell 20, 248–263 (2015).

14. Burger, A., Koesters, R., Schäfer, B. W. & Niggli, F. K. Generation of a novel iPSC transgenic mouse to induce time-controlled, tissue-specific alterations in Pax2-expressing cells. Genesis 49, 797–802 (2011).

15. Winyard, P. J., Risdon, R. A., Sams, V. R., Dressler, G. R. & Woolf, A. S. The Pax2 transcription factor is expressed in cystic and hyperproliferative dysplastic epithelia in human kidney malformations. J. Clin. Invest. 98, 451–459 (1996).

16. Cianciolo Costantino, C. et al. Histone deacetylase inhibitor enhances recovery after AKI. J. Am. Soc. Nephrol. 24, 943–953 (2013).

17. Levine, M. H. et al. Class-specific histone/protein deacetylase inhibition protects against renal ischemia reperfusion injury and fibrosis formation. Am. J. Transplant. 15, 965–973 (2015).
18. Novitskaya, T. et al. A PTBA class small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. *Am. J. Physiol. Ren. Physiol.* 306, F496–F504 (2014).

19. de Groh, E. D. et al. Inhibition of histone deacetylase expands the renal progenitor cell population. *J. Am. Soc. Nephrol.* 21, 794–802 (2010).

20. Maga, G. & Hubscher, U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. *J. Cell Sci.* 11, 3051–3060 (2003).

21. Sakaue-Sawano, A. et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. *Cell* 132, 487–498 (2008).

22. Rocco, M., Schmitter, D., Knobloch, M., Okawa, Y. & Sage, D. Predicting stem cell fate changes by differential cell-cycle progression patterns. *Development* 140, 459–470 (2013).

23. Kaminski, M. M. et al. Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors. *Nat. Cell Biol.* 18, 1269–1280 (2016).

24. Naiman, N. et al. Repression of interstitial identity in nephron progenitor cells by Pax2 establishes the nephron-interstitium boundary during kidney development. *Dev. Cell* 41, 349–365 (2017).

25. Yang, L., Beschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell-cycle arrest in G2/M mediates kidney fibrosis after injury. *Nat. Med.* 16, 535–543 (2010).

26. Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell-cycle arrest and parenchymal damage in renal fibrosis. *Nat. Med.* 21, 998–1009 (2015).

27. Wang, F. & Higgins, J. M. Histone modifications and mitotic countermarks, landmarks, and bookmarks. *Trends Cell Biol.* 23, 175–184 (2013).

28. Edgar, R. A., Zielke, N. & Gutierrez, C. Endocytes: a recurrent evolutionary innovation for post-mitotic cell growth. *Nat. Rev. Mol. Cell Biol.* 15, 197–210 (2014).

29. Mort, R. L. et al. Fucci2a: a bicistronic cell cycle reporter that allows Cre mediated tissue specific expression in mice. *Cell Cycle* 13, 2681–2696 (2014).

30. Wang, Z. et al. Migratory localization of cyclin D2-Cdk4 complex suggests a spatial regulation of the G1-S transition. *Cell Struct. Funct.* 33, 171–183 (2008).

31. Cuppage, F. E. & Tate, A. Repair of the nephron following injury with mercuric chloride. *Am. J. Pathol.* 51, 405–429 (1967).

32. Basile, D. P., Anderson, M. D. & Sutton, T. A. Pathophysiology of acute kidney injury. *Compr. Physiol.* 2, 1363–1353 (2012).

33. Kumar, S. et al. Sox9 activation highlights a cellular pathway of renal repair in the acutely injured mammalian kidney. *Cell Rep.* 12, 1325–1338 (2015).

34. Kang, H. M. et al. Sox9-positive progenitor cells play a key role in renal tubule epithelial regeneration in mice. *Cell Rep.* 14, 861–871 (2016).

35. Wang, B., Zhao, L., Fish, M., Logan, C. Y. & Nusse, R. Self-renewing diploid Axin2(−) cells fuel homeostatic renewal of the liver. *Nature* 524, 180–185 (2015).

36. Kusaba, T., Lalli, M., Kramann, R., Kobayashi, A. & Humphreys, B. D. Differentiated kidney epithelial cells repair injured proximal tubule. *Proc. Natl Acad. Sci. USA* 111, 1527–1532 (2014).

37. Berger, K. et al. Origin of regenerating tubular cells after acute kidney injury. *Proc. Natl Acad. Sci. USA* 111, 1533–1538 (2014).

38. Romagnani, P., Rinkevich, Y. & Dekel, B. The use of lineage tracing to study kidney injury and regeneration. *Nat. Rev. Nephrol.* 11, 420–431 (2015).

39. Ganem, N. J. et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. *Cell* 158, 833–848 (2014).

40. Tamori, Y. & Deng, W. M. Tissue repair through cell competition and compensatory cellular hypertrophy in postmitotic epithelia. *Dev. Cell* 25, 350–363 (2013).

41. Kriz, W. & LeHir, M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. *Kidney Int.* 67, 404–419 (2005).

42. Mulay, S. R. et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. *Am. J. Physiol. Renal. Physiol.* 310, F785–F795 (2016).

43. Friedemann, J. et al. Improved kinetic model for the transcutaneous measurement of glomerular filtration rate in experimental animals. *Kidney Int.* 90, 1377–1385 (2016).

44. Gu, L., Cong, J., Zhang, J., Tian, Y. Y. & Zhai, X. Y. A microwave antigen retrieval method using two heating steps for enhanced immunostaining on aldehyde-fixed paraffin-embedded tissue sections. *Histochem. Cell Biol.* 145, 675–680 (2016).

45. Lazzeri, E. et al. Human urine-derived renal progenitors for personalized modeling of genetic kidney disorders. *J. Am. Soc. Nephrol.* 26, 1961–1974 (2015).

46. KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int. Suppl.* 2, 1–138 (2012).

### Acknowledgements

This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement N° 648274) to P.R. H.-J.A. is supported by the Deutsche Forschungsgemeinschaft (AN372/1-2, 17-1, 23-1, and 24-1) and the BMBF (REPLACE-AKI 031L0071).

### Author contributions

P.R., with the help of E.L., as well as M.L.A. conceived of the study. E.L., M.L.A., F.B. and C.C. designed and performed immunofluorescence and confocal microscopy. E.L., A.P., L.M., C.C., M.E.M., L.D.C. and F.A. designed and performed flow cytometry and cell cycle analysis. A.P., C.C., G.A., E.R., D.L., S.N. and M.E.M designed and performed experiments in the mouse systems. B.M., R.R.G. and A.S. designed and performed in vitro experiments. J.A.M. and H.-J.A. performed GFP analysis. A.B. and R.S. provided the PAX2CreTA mice. L.M., M.L.A., E.L. and P.R. analyzed the data. L.M., M.L.A., E.L. and H.-J.A. critically revised the manuscript. P.R. wrote the paper with input from all authors.

### Additional information

**Supplementary Information** accompanies this paper at https://doi.org/10.1038/s41467-018-03753-4.

**Reprints and permissions information** is available online at http://npg.nature.com/reprintsandpermissions/

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018